Navigation Links
MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
Date:9/10/2013

ry and pre-clinical development of PWT143 to date," said Julie Cherrington, Ph.D., President and Chief Executive Officer of Pathway Therapeutics. "We continue to believe strongly in its potential to be an important drug for patients, and we are pleased that it is going into the hands of a team with the resources and drug development expertise to maximize that potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza (azacitidine) in patients with MDS presented at the American Society of Hematology Annual Meeting in December 2012 showed an overall response rate of 89% (eight out of nine). In June 2013, the Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated MDS. An open-label Phase II trial of Pracinostat in combination with Vidaza in elderly patients with AML unsuitable for induction therapy is expected to initiate in the fall of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a first-in-human Phase I trial of ME-344 in patients with solid refractory tumors are anticipated in October 2013. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe a
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
3. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
4. Pharmaceutical Giants Back Researchers in Unique US Competition
5. Several Market Access Drivers Provide Attractive Opportunities for Multinational Companies in Saudi Arabias Pharmaceutical Market
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. Sunshine Act 2013 Updates: A Checklist for Pharmaceutical Companies to Meet CMS Reporting
8. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
9. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
10. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
11. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has ... the college expand its reach and impact through innovative technologies and strategies. , “I ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... On Saturday, ... Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational program titled ... 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... may extend and improve the lives of patients, according to a newly published ... here to read the full article. , The authors of the new ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... ANGELES (May 5, 2010) High doses of antioxidant ... genetic abnormalities in cells, which may predispose supplement-takers to developing ... Institute. The study, led by Eduardo Marbn, ... online today in the medical journal Stem Cells . ...
... ... launches their professional organization business specializing in all areas of the home. ... (PRWEB) ... market this month. The company’s mission is to create fabulous homes through ...
... stroke , TUESDAY, May 4 (HealthDay News) -- Being ... attack or stroke in men older than 45, a new ... ages 45 to 69, who enrolled in the California Men,s ... followed until Dec. 31, 2007. , During the follow-up, there ...
... experts say , TUESDAY, May 4 (HealthDay News) -- While rates ... the United States, a new study finds that among young, white ... of lower stomach cancer is infection with the bacteria Helicobacter ... by acid reflux. Most stomach cancers are found in those aged ...
... works in different fashion than the current widely accepted ... of the drugparticularly in people with cancer and diseases ... (LAM). The results of this study, led ... Diseases Institute, are published in the May 5 edition ...
... A medication most often used to treat heart arrhythmias also ... type of muscular dystrophy in adults. The findings about ... were published May 4 in the journal Neurology , ... there is no drug approved to treat myotonic dystrophy, an ...
Cached Medicine News:Health News:High doses of antioxidant supplements induce stem cell genetic abnormalities 2Health News:Stomach Cancer on the Rise Among Young, White Adults 2Health News:Stomach Cancer on the Rise Among Young, White Adults 3Health News:Popular diabetes drug works differently than thought 2Health News:Heart drug effective for treating symptom of muscular dystrophy 2Health News:Heart drug effective for treating symptom of muscular dystrophy 3
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: